Every open market buy and sale of Arcutis Biotherapeutics, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $14M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when ARQT insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an ARQT officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every ARQT insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Howard G. WelgusDirector | Sale plan | 4,728 | $28.16 | $133K | 34,573 | Nov 18Form 4 |
| Nov 4, 2026 | Masaru MatsudaEVP, Chief Legal Officer | Sale plan | 41,219 | $34.24 | $1.4M | 111,289 | Nov 4Form 4 |
| Nov 2, 2026 | Todd WatanabeSee Remarks | Sale | 4,377 | $31.86 | $139K | 712,826 | Nov 4Form 4 |
| Nov 2, 2026 | Patrick BurnettEVP, Chief Medical Officer | Sale | 943 | $31.86 | $30K | 116,649 | Nov 4Form 4 |
| Oct 15, 2026 | Howard G. WelgusDirector | Sale plan | 4,728 | $26.93 | $127K | 35,207 | Oct 19Form 4 |
| Sep 16, 2026 | Masaru MatsudaSee Remarks | Sale plan | 3,674 | $25.00 | $92K | 112,508 | Sep 18Form 4 |
| Sep 15, 2026 | Howard G. WelgusDirector | Sale plan | 4,730 | $24.18 | $114K | 35,841 | Sep 17Form 4 |
| Sep 8, 2026 | Masaru MatsudaSee Remarks | Sale plan | 9,989 | $25.03 | $250K | 116,182 | Sep 10Form 4 |
| Aug 27, 2026 | Terrie CurranDirector | Sale | 38,200 | $25.03 | $956K | 23,526 | Aug 28Form 4 |
| Aug 20, 2026 | Terrie CurranDirector | Sale | 1,072 | $26.04 | $28K | 23,526 | Aug 24Form 4 |
| Aug 19, 2026 | Patrick BurnettSee Remarks | Sale | 1,697 | $27.00 | $46K | 117,592 | Aug 21Form 4 |
| Aug 17, 2026 | Howard G. WelgusDirector | Sale plan | 4,730 | $26.18 | $124K | 36,475 | Aug 19Form 4 |
| Aug 12, 2026 | Patrick BurnettSee Remarks | Sale | 15,000 | $26.33 | $395K | 119,289 | Aug 13Form 4 |
| Aug 3, 2026 | Todd WatanabeSee Remarks | Sale plan | 4,375 | $26.12 | $114K | 717,203 | Aug 5Form 4 |
| Aug 3, 2026 | Masaru MatsudaSee Remarks | Sale plan | 1,230 | $26.12 | $32K | 126,171 | Aug 5Form 4 |
ARQT insider trading FAQ
Are ARQT insiders buying or selling?
Insiders are only selling over the last 12 months. 0 insiders bought $0 of ARQT on the open market in 0 trades, and 10 sold $14M in 49 trades, 80% of that under pre-arranged trading plans.
When did an ARQT insider last buy shares?
Patrick J Heron (Director) bought 2,646 shares for $35K on Jun 13, 2025, reported on Jun 17, 2025.
When did an ARQT insider last sell shares?
Howard G. Welgus (Director) sold 4,728 shares for $133K on Nov 16, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
